Trials / Terminated
TerminatedNCT05633160
64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)
A Phase I/IIa Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Clarity Pharmaceuticals Ltd · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim for this study is to determine the safety and efficacy of 67Cu-SAR-BBN in participants with Gastrin Releasing Peptide Receptor (GRPR)-expressing metastatic castrate resistant prostate cancer in patients who are ineligible for therapy with 177Lu-PSMA-617.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 64Cu-SAR-BBN | 64Cu-SAR-BBN |
| DRUG | 67Cu-SAR-BBN | 67Cu-SAR-BBN |
Timeline
- Start date
- 2023-06-15
- Primary completion
- 2025-04-23
- Completion
- 2025-04-23
- First posted
- 2022-12-01
- Last updated
- 2025-08-29
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05633160. Inclusion in this directory is not an endorsement.